Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Jacobio Pharma-B (02617.HK) Completes First Patient Dosing in Phase III Trial of Tinengotinib
Recommend 2 Positive 3 Negative 0 |
||||
|
||||
|
Jacobio Pharma-B (02617.HK) announced that the confirmatory Phase III clinical study of its core product Tinengotinib (TT-00420) as a monotherapy for patients with advanced cholangiocarcinoma has recently completed dosing of the first patient. Tinengotinib is an innovative multi-target small-molecule kinase inhibitor independently developed by the company and currently at the new drug application stage. It exerts anti-tumor effects by targeting tumor cells and improving the tumor microenvironment. (de/d) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
